Bognár Laura, Hegedűs Ivett, Bellyei Szabolcs, Pozsgai Éva, Zoltán László, Gombos Katalin, Horváth Örs Péter, Vereczkei András, Papp András
1Department of Surgery, Medical School, University of Pécs, Hungary, Ifjuság Street 13, Pécs, 7624 Hungary.
2Department of Pathology, Medical School, University of Pécs, Hungary, Szigeti Street 12, Pécs, 7624 Hungary.
Infect Agent Cancer. 2018 Nov 29;13:38. doi: 10.1186/s13027-018-0210-9. eCollection 2018.
The aims of this study were to evaluate whether HPV infection has a prognostic role in patients with esophageal squamous cell carcinoma who underwent oncological treatment and also to compare the heat shock proteins (Hsp) 90, 27 and 16.2 and growth hormone-releasing hormone receptor (GHRH-R) expression patterns of the pre-treatment tumor biopsies with the HPV status and with the oncological response.
Pre-treatment tumor biopsies of 74 patients with locally advanced esophageal squamous cell carcinoma were processed retrospectively. The presence of HPV was detected by chromogenic in situ hybridization. Hsp and GHRH-R expressions were determined using immunohistochemistry. Following neoadjuvant or definitive radiochemotherapy, the patients were restaged according to the Response Evaluation Criteria in Solid Tumors. The correlation between the HPV status, response to treatment and Hsp and GHRH-R expressions were evaluated.
Fourteen (19%) patients were HPV-positive. These patients were more likely to respond poorly to multimodal therapy (71.4% were non-responders vs. 28.6% responders) and had shorter survival compared to HPV-negative patients (mean survival of 8 months vs. 11 months), although the difference was not significant. A significantly higher number of HPV-positive patients expressed Hsp 90 and 16.2 at high levels (93 and 79%, respectively) than at low levels (Chi-Square = 0.019 and = 0.031). Higher levels of Hsp expressions were associated with poorer response to therapy and worse overall survival. No correlation was found between GHRH-R expression and the HPV status, nor between GHRH-R expression and the treatment response of the examined samples.
We found that HPV infection was associated with poor response to oncological treatment and decreased overall survival, and therefore proved to be a negative prognostic factor in patients with esophageal squamous cell carcinoma. There was a linear correlation between levels of Hsp 90 and 16.2 expression and HPV positivity.
本研究的目的是评估人乳头瘤病毒(HPV)感染在接受肿瘤治疗的食管鳞状细胞癌患者中是否具有预后作用,同时比较治疗前肿瘤活检组织中热休克蛋白(Hsp)90、27和16.2以及生长激素释放激素受体(GHRH-R)的表达模式与HPV状态及肿瘤反应情况。
回顾性分析74例局部晚期食管鳞状细胞癌患者的治疗前肿瘤活检组织。采用显色原位杂交检测HPV的存在情况。运用免疫组织化学法测定Hsp和GHRH-R的表达。在新辅助或根治性放化疗后,根据实体瘤疗效评价标准对患者进行重新分期。评估HPV状态、治疗反应与Hsp和GHRH-R表达之间的相关性。
14例(19%)患者HPV呈阳性。与HPV阴性患者相比,这些患者对多模式治疗的反应较差(71.4%为无反应者,而反应者为28.6%),且生存期较短(平均生存期分别为8个月和11个月),尽管差异不显著。HPV阳性患者中高水平表达Hsp 90和16.2的人数显著多于低水平表达者(分别为93%和79%)(卡方值分别为0.019和0.031)。Hsp表达水平较高与治疗反应较差及总生存期较差相关。未发现GHRH-R表达与HPV状态之间存在相关性,也未发现GHRH-R表达与所检测样本的治疗反应之间存在相关性。
我们发现HPV感染与肿瘤治疗反应差及总生存期缩短相关,因此被证明是食管鳞状细胞癌患者的一个负性预后因素。Hsp 90和16.2的表达水平与HPV阳性之间存在线性相关性。